Entresto Archives -

Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance has become the first drug in the class to be

Jardiance pulls ahead of Forxiga with heart failure approval in EU

https://pharmaphorum.com/news/jardiance-pulls-ahead-of-forxiga-in-european-heart-failure-market/

Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, Farxiga, heart failure, Jardiance, Novartis 0 Comment

Boehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance

Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure

https://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/

Market Access/ News/ News

Entresto set for big sales hike after FDA panel endorsement

Phil Taylor cardiology, Entresto, fda, heart failure, Novartis 0 Comment

Novartis’ Entresto is on course to become the first drug to be approved in the US for a

Entresto set for big sales hike after FDA panel endorsement

https://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement/

News/ News/ Sales and Marketing

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

Phil Taylor coronavirus, Cosentyx, COVID-19, Entresto, Financial, Kisqali, Novartis, Zolgensma 0 Comment

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilise

https://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/

News/ News/ R&D

Despite trial miss, Novartis still believes in Entresto for HFpEF

Phil Taylor cardiovascular disease, Entresto, heart failure, Novartis 0 Comment

Novartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction

Despite trial miss, Novartis still believes in Entresto for HFpEF

https://pharmaphorum.com/news/despite-trial-miss-novartis-still-believes-in-entresto-for-hfpef/

News/ News/ R&D

Entresto tops mainstay ACE inhibitor in heart failure trial

Phil Taylor Entresto, heart failure drug, Novartis 0 Comment

Two years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope

Entresto tops mainstay ACE inhibitor in heart failure trial

https://pharmaphorum.com/news/entresto-tops-mainstay-ace-inhibitor-in-heart-failure-trial/

Articles/ Brexit/ Clinical/ Pharma Market Access/ R&D/ UK & Europe/ US/ Views and analysis

The biggest pharma stories of 2016 so far

Linda Banks Adaptive Pathways, Allergan, AZ, Brexit, Duchenne, Entresto, Gliead, GSK, Hep C, Iqwig, market access, Novartis, Pfizer, pharma, regulators, Theranos 0 Comment

The top 10 pharma milestones of the year to date.

The biggest pharma stories of 2016 so far

https://pharmaphorum.com/views-and-analysis/biggest-pharma-stories-2016-far/

News/ Sales and Marketing

Novartis ramping up investment in new drugs

Richard Staines cancer, cardiology, Entresto, Novartis, sales 0 Comment

Swiss pharma loses patent on key cancer drug

Novartis ramping up investment in new drugs

https://pharmaphorum.com/news/novartis-ramping-investment-new-drugs/

Articles/ Views and analysis

10 drugs – and their prices – which changed pharma in 2015

Andrew McConaghie Entresto, FDA approvals, ICER, Opdivo, Orkambi 0 Comment

In a record-breaking year for pharma, which drugs were the most outstanding?

10 drugs – and their prices – which changed pharma in 2015

https://pharmaphorum.com/views-and-analysis/10-drugs-and-their-prices-which-changed-pharma-in-2015/

Trending

Entresto

Login